APA (7th ed.) Citation

Remon, J., Besse, B., Aix, S. P., Callejo, A., Al-Rabi, K., Bernabe, R., . . . Fournier, B. (2023). Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial. Annals of Oncology, 34(5), 468. https://doi.org/10.1016/j.annonc.2023.02.012

Chicago Style (17th ed.) Citation

Remon, J., et al. "Osimertinib Treatment Based on Plasma T790M Monitoring in Patients with EGFR-mutant Non-small-cell Lung Cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE Phase II Randomized Clinical Trial." Annals of Oncology 34, no. 5 (2023): 468. https://doi.org/10.1016/j.annonc.2023.02.012.

MLA (9th ed.) Citation

Remon, J., et al. "Osimertinib Treatment Based on Plasma T790M Monitoring in Patients with EGFR-mutant Non-small-cell Lung Cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE Phase II Randomized Clinical Trial." Annals of Oncology, vol. 34, no. 5, 2023, p. 468, https://doi.org/10.1016/j.annonc.2023.02.012.